Showing results (61-70 of 168) with videos related to

Sort By:
Pageof 17
Advances in Therapy|September 24, 2024
Macitentan and Tadalafil Combination Therapy in Incident and Prevalent Pulmonary Arterial Hypertension: Real-World Evidence from the OPUS/OrPHeUS StudiesKelly M Chin, Richard Channick, Nick H Kim, et al.
Chest|October 16, 2004
Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertensionJacques I Benisty, Vallerie V McLaughlin, Michael J Landzberg, et al.
Cardiology and Therapy|November 25, 2024
Macitentan in Pulmonary Arterial Hypertension Due to Congenital Heart Disease (CHD-PAH): Real-World Evidence from the OPUS/OrPHeUS StudiesKelly M Chin, Richard Channick, Nick H Kim, et al.
Advances in Therapy|May 19, 2025
Macitentan and Tadalafil Combination Therapy in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities: Real-World Evidence from OPUS and OrPHeUSNick H Kim, Kelly M Chin, Vallerie V McLaughlin, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|September 5, 2024
Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trialsStephan Rosenkranz, Hossein-Ardeschir Ghofrani, Marius M Hoeper, et al.
American Journal of Respiratory and Critical Care Medicine|September 10, 2005
Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertensionMardi Gomberg-Maitland, Victor F Tapson, Raymond L Benza, et al.
JACC. Advances|June 28, 2024
Timely PAH Identification in Adults With Repaired Congenital Heart Disease? The ACHD-QuERI Registry InsightsMichael J Landzberg, Curt J Daniels, Paul Forfia, et al.
Chest|July 14, 2004
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelinesDavid B Badesch, Steve H Abman, Gregory S Ahearn, et al.
Chest|March 16, 2006
Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trialVictor F Tapson, Mardi Gomberg-Maitland, Vallerie V McLaughlin, et al.
Pulmonary Circulation|September 29, 2022
Using a knowledge translation program to facilitate guideline- and evidence-based patient management: the PAH-QuERI Extension ProgramVallerie V McLaughlin, Richard N Channick, Karimah S Bell Lynum, et al.
Pageof 17